聚乙二醇化重组人粒细胞刺激因子二级预防卵巢癌化疗后中性粒细胞减少的疗效分析

Efficacy of Pegylated Recombinant Human Granulocyte-stimulating Factor in the Secondary Prevention of Neutropenia after Chemotherapy in Ovarian Cancer

目的探析聚乙二醇化重组人粒细胞刺激因子(Pegylated recombinant human granulocyte colonystimulating factor,PEG-rhG-CSF)二级预防卵巢癌化疗后中性粒细胞减少的临床疗效。方法方便选取2019年1月—2021年10月盐城市第三人民医院收治的采取“紫杉醇+顺铂/卡铂”方案化疗且上一周期出现Ⅲ~Ⅳ度中性粒细胞减少的卵巢癌患者44例,随机分为观察组和对照组,各22例。观察组在化疗结束24 h后给予PEG-rhG-CSF单次皮下注射,对照组在化疗结束24 h后给予重组人粒细胞刺激因子(recombinant human granulocytestimulating factor,rhG-CSF)每日皮下注射。统计两组患者中性粒细胞绝对值减少发生率、中性粒细胞减少性发热发生率、不良反应发生率及生活质量。结果观察组Ⅲ~Ⅳ度ANC减少发生率(27.27%)低于对照组(36.36%),但差异无统计学意义(χ^(2)=0.419,P>0.05)。两组中性粒细胞减少性发热及不良反应发生率比较,差异无统计学意义(P>0.05)。两组生活质量评分比较,差异有统计学意义(P<0.05)。结论PEGrhG-CSF用于卵巢癌患者化疗后的二级预防,疗效确切,可降低Ⅲ~Ⅳ度ANC发生率,且应用方便,患者生活质量得到改善。

Objective To explore the clinical efficacy of PEGylated recombinant human granulocyte colonystimulating factor(PEG-rhG-CSF)in the secondary prevention of neutropenia after chemotherapy for ovarian cancer.Methods 44 ovarian cancer patients who underwent chemotherapy with the"paclitaxel+cisplatin/carboplatin"regimen and experienced gradeⅢ-Ⅳneutropenia in the previous cycle and were admitted to Yancheng Third People's Hospital from January 2019 to October 2021 were conveniently selected and randomly divided into an observation group and a control group,with 22 cases in each group.The observation group received a single subcutaneous injection of PEG-rhG-CSF 24 hours after chemotherapy,while the control group received daily subcutaneous injection of recombinant human granulocyte stimulating factor(rhG-CSF)24 hours after chemotherapy.Calculate the incidence of number of neutrophil in peripheral blood,neutropenia induced fever,adverse reactions,and quality of life in two groups of patients.Results The incidence of degreeⅢ-ⅣANC reduction in the observation group(27.27%)was lower than that in the control group(36.36%),but the difference was not statistically significant(χ^(2)=0.419,P>0.05).There was no statistically significant difference in the incidence of neutropenia induced fever and adverse reactions between the two groups(P>0.05).Comparison of quality of life scores between two groups,the difference was statistically significant(P<0.05).Conclusion PEG-rhG-CSF is used for the secondary prevention of ovarian cancer patients after chemotherapy.It has a definite curative effect and can reduce the incidence of gradeⅢ-ⅣANC.It is convenient to use and improves the quality of life of patients.